Twitter timeline

Oncodesign announces positive results opening the way for the ALK1 program to advance to the lead optimization phase

November 15, 2017

  • Activin receptor-like kinase 1 (ALK1) is a target involved in angiogenesis with promising applications in cancer therapies
  • The program has identified highly targeted inhibitor molecules and produced promising cellular results paving the way for lead optimization to begin